Represented appellee Watson Pharmaceuticals, Inc. in successful defense of district court’s order dismissing Bayer’s claims of patent infringement. The Federal Circuit agreed with Watson that for a generic drug maker to infringe a method-of-use patent, the proposed label must indicate that the drug is approved (i.e., safe and effective) for the claimed method. Bayer Schering Pharma AG v. Lupin, Ltd., et al., 2012 U.S. App. LEXIS 7570, Fed. Cir. Appeal No. 2011-1143 (April 16, 2012).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Transactions for brokerage firms
Represented one of the leading U.S.-based brokerage firms in commercial loan transactions for its brokerage customers; loans secured by real and more
Governance litigation for a health care services company
Represented a health care services company in wide-ranging disputes and litigation with a minority member who asserted a variety of breach of more
Environmental services for largest trade organization in the home furnishings industry
Serves as national environmental counsel to world's largest and most influential trade organization serving the home furnishings industry, where we more
Patent and trademark portfolio management work for Renfro Corporation
We are outside IP counsel to this company, which is the world's largest manufacturer of socks under such well-known brands as POLO, RALPH LAUREN, HOT more